[PDF][PDF] An insulin hypersecretion phenotype precedes pancreatic β cell failure in MODY3 patient-specific cells

FM Hermann, MF Kjærgaard, C Tian, U Tiemann… - Cell Stem Cell, 2023 - cell.com
FM Hermann, MF Kjærgaard, C Tian, U Tiemann, A Jackson, LR Olsen, M Kraft…
Cell Stem Cell, 2023cell.com
MODY3 is a monogenic hereditary form of diabetes caused by mutations in the transcription
factor HNF1A. The patients progressively develop hyperglycemia due to perturbed insulin
secretion, but the pathogenesis is unknown. Using patient-specific hiPSCs, we recapitulate
the insulin secretion sensitivity to the membrane depolarizing agent sulfonylurea commonly
observed in MODY3 patients. Unexpectedly, MODY3 patient-specific HNF1A+/R272C β
cells hypersecrete insulin both in vitro and in vivo after transplantation into mice …
Summary
MODY3 is a monogenic hereditary form of diabetes caused by mutations in the transcription factor HNF1A. The patients progressively develop hyperglycemia due to perturbed insulin secretion, but the pathogenesis is unknown. Using patient-specific hiPSCs, we recapitulate the insulin secretion sensitivity to the membrane depolarizing agent sulfonylurea commonly observed in MODY3 patients. Unexpectedly, MODY3 patient-specific HNF1A+/R272C β cells hypersecrete insulin both in vitro and in vivo after transplantation into mice. Consistently, we identified a trend of increased birth weight in human HNF1A mutation carriers compared with healthy siblings. Reduced expression of potassium channels, specifically the KATP channel, in MODY3 β cells, increased calcium signaling, and rescue of the insulin hypersecretion phenotype by pharmacological targeting ATP-sensitive potassium channels or low-voltage-activated calcium channels suggest that more efficient membrane depolarization underlies the hypersecretion of insulin in MODY3 β cells. Our findings identify a pathogenic mechanism leading to β cell failure in MODY3.
cell.com